Bernstein raised the firm’s price target on Alnylam to $220 from $216 and keeps an Outperform rating on the shares. The firm expects HELIOS-B to be a significant binary event for the stock, with downside of about 50% if the trial fails, and a range of upside scenarios potentially as high as 40%-plus. Bernstein has conviction the trial will not only succeed but also clearly differentiate Amvuttra vs. stabilizers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALNY:
- William Blair sees ATTR-PN market as large enough for two players
- Citi says approval ‘likely’ for Ionis’ eplontersen ATTR-PN NDA
- Alnylam price target raised by $7 at Piper Sandler, here’s why
- Alnylam price target raised by $7 at BofA, here’s why
- Alnylam to hold a virtual research and development day
